Skip to main content
. 2016 Feb 1;12(5):1300–1310. doi: 10.1080/21645515.2015.1136040

Figure 6.

Figure 6.

Percentages of subjects with hSBA titers ≥8 and 95% CIs (error bars) pre-booster and at 1 month after booster dose of MenACWY-CRM given 3 y after a single primary dose of MenACWY-CRM in adolescents aged 11–18 y (Study 3) or 5 y after a single dose in children aged 2–5 and 6–10 y of age (Study 4), or 5 y after 2-dose primary vaccination series in toddlers 12–24 months of age or 4-dose primary series in infants aged 2 months (Study 7), by serogroup.